In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's Landwind Device Maker Reported Target Of U.S. Acquisition

This article was originally published in PharmAsia News

Executive Summary

Chinese medical-device maker Landwind is said to be the target of an acquisition effort by the U.S.-based hedge fund, Avenue Capital

Chinese medical-device maker Landwind is said to be the target of an acquisition effort by the U.S.-based hedge fund, Avenue Capital.

Sources said the deal for Landwind could be worth more than $100 million. Avenue Capital, working with Citi Venture Capital International, is reported to be in the last stage of acquisition talks after other would-be investors ceased bidding for the company. None of the parties involved would confirm the deal. (Click here for more)

"Avenue Capital Nears Deal For China Medical Firm--Sources" - Reuters (U.K.) (10/20/09)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel